Making effective decisions in health care requires a thorough understanding of the patient perspective, as well as robust, precise measures of response to therapy. The Patient Access & Affordability Project evaluates the various frameworks used to assess and demonstrate the value of new treatments to ensure that the patient is kept at the center of health care decisions.
Get Updates in Your Inbox
Sign Up. Stay Informed.
The Conversation
PRESS RELEASE: Patients Rising Releases New Rare Disease Drug Assessment Standards Aimed at Improving Health Equity
Press Contact: Sarah Shelsonsshelson@riesterpublicaffairs.com New framework for the evaluation of rare disease therapies prioritizes patient experiences, feedback, and needs WASHINGTON — Patients Rising, a non-profit organization that advocates on behalf of patients...
Healthcare That is Fit for Service
Veterans Have An Urgent Need for Better HealthcareVeterans are American heroes that deserve the highest level of respect, care and dignity that our nation can offer. Yet, Uncle Sam has fallen short on the promise to have the backs of the men and women who wore the...
ICER’s Latest: A draft evidence report on treatments for vasomotor symptoms of menopause
On October 11, 2022 2021, ICER released a draft evidence report, “Fezolinetant for Moderate to Severe Vasomotor Symptoms Associated with Menopause.” This is the first step in ICER’s assessment process that is current scheduled to conclude with the release of a final...
Op-Ed: Medicare’s cuts to home health are a step in the wrong direction
By Terry Wilcox
Co-Founder and CEO, Patients Rising
ICER’s Latest: A draft evidence report on gene therapies for Hemophilia A and B
On September 13, 2022 2021, ICER released a new draft evidence report, “Gene Therapy for Hemophilia B and An Update on Gene Therapy for Hemophilia A.” This is the first step in ICER’s process that is expected to conclude with the release of a final report in December...
ICER’s Latest: A draft evidence report on medications for obesity management
On July 13, 2022 2021, ICER released its draft evidence report, “Medications for Obesity Management.” This is the first step in ICER’s process that is expected to conclude with the release of a final report in October 2022. ICER’s report reviews four medicines...